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Abstract
Objective: ITPR3, encoding inositol 1,4,5-trisphosphate receptor type 3, was
previously reported as a potential candidate disease gene for Charcot-Marie-
Tooth neuropathy. Here, we present genetic and functional evidence that ITPR3
is a Charcot-Marie-Tooth disease gene. Methods: Whole-exome sequencing of
four affected individuals in an autosomal dominant family and one individual
who was the only affected individual in his family was used to identify disease-
causing variants. Skin fibroblasts from two individuals of the autosomal domi-
nant family were analyzed functionally by western blotting, quantitative reverse
transcription PCR, and Ca2+ imaging. Results: Affected individuals in the auto-
somal dominant family had onset of symmetrical neuropathy with demyelinat-
ing and secondary axonal features at around age 30, showing signs of gradual
progression with severe distal leg weakness and hand involvement in the pro-
band at age 64. Exome sequencing identified a heterozygous ITPR3 p.Val615-
Met variant segregating with the disease. The individual who was the only
affected in his family had disease onset at age 4 with demyelinating neuropathy.
His condition was progressive, leading to severe muscle atrophy below knees
and atrophy of proximal leg and hand muscles by age 16. Trio exome sequenc-
ing identified a de novo ITPR3 variant p.Arg2524Cys. Altered Ca2+-transients in
p.Val615Met patient fibroblasts suggested that the variant has a dominant-nega-
tive effect on inositol 1,4,5-trisphosphate receptor type 3 function. Interpreta-
tion: Together with two previously identified variants, our report adds further
evidence that ITPR3 is a disease-causing gene for CMT and indicates altered
Ca2+ homeostasis in disease pathogenesis.
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INTRODUCTION
Charcot-Marie-Tooth disease (CMT) is a group of heredi-
tary neuropathies, characterized by progressive distal sen-
sory and motor impairment, which affects 1:2500
individuals.1 The disease is categorized into demyelinating
CMT1, where median motor nerve conduction velocity
(NCV) is < 38 m/s and axonal CMT2 where median
motor NCV is> 38 m/s but compound muscle action
potentials are (CMAP) decreased. Cases with features of
both demyelination and axonopathy and NCV in the 30-
45 m/s range are sometimes referred to as intermediate
CMT.2 A large number of CMT disease gene discoveries
have led to insights of the disease mechanisms and poten-
tial therapies.3 Dominant variants in ITPR3, which
encodes the inositol 1,4,5-trisphosphate (IP3) receptor
(IP3R) type 3, were recently suggested as potential causes
of CMT.4,5 Linkage analysis combined with exome
sequencing revealed a p.Thr1424Met variant that segre-
gated with a CMT phenotype in three patients from a sin-
gle family.4 Furthermore, gene panel screening found a
p.Met1064Val variant in a single index case for which no
additional clinical details were provided.5 The pathogenic-
ity of these variants was not confirmed by functional stud-
ies or by segregation of the variants in additional families.
Humans have three IP3R isoforms: IP3R1, IP3R2, and
IP3R3. They are homologous in sequence but differ in
physiological functions and tissue expression.6,7 IP3 is
produced after activation of G protein coupled receptors
(GPCR), and binds the tetrameric IP3Rs, which release
Ca2+ from ER into cytoplasm.8 The resulting elevation of
intracellular Ca2+ concentration has several downstream
effects on the cell.9 The importance of IP3R signaling in
neurons is underscored by the defects in IP3R1 leading to
ataxia or Gillespie syndrome.10-13 Furthermore, the ER
associated degradation pathway of activated IP3Rs is dis-
rupted by inactivating variants in the genes ERLIN1,
ERLIN2, and RNF170, causing hereditary spastic paraple-
gia and other neurodegenerative diseases.14,15 IP3R3 itself
has been implicated in apoptosis control, while alterations
in its activity and/or expression levels drive oncogenesis
and impact the survival of malignant cells.16,17
In this study, we provide confirmatory evidence of the
association of ITPR3 with CMT. We introduce a CMT fam-
ily with autosomal dominant mutation and one case with de
novomutation in ITPR3. In addition, we provide functional
evidence of altered Ca2+ dynamics in patient fibroblasts.
METHODS
Patients and sequencing
Individuals P1, P2, P3, and P4 gave written informed con-
sent and the ethics review board of HUS Helsinki Univer-
sity Hospital approved the study. Control fibroblast cells
were from anonymous donors, who consented to use of the
cells in scientific research. The fibroblast cells were collected
from skin biopsy and cultured in Dulbecco’s Modified
Eagle Medium (DMEM), supplemented with 10% FBS (Life
Technologies), 1% penicillin/streptomycin (Life Technolo-
gies), 1% L-glutamine (Life Technologies), and 0.2% uri-
dine (Sigma). Cells were incubated at 37 °C in 5 % CO2.
Exome sequencing for the Finnish family was per-
formed as described previously.18 Sanger sequencing pri-
mers are shown in Table S1. Research trio whole-exome
sequencing (WES) was done on individual P5 and parents
after written informed consent was obtained through an
institutional review board-approved research study at the
Institute for Genomic Medicine at Columbia University
(protocol AAAO8410). DNA was extracted from mater-
nal, paternal, and proband samples, exome sequenced on
a HiSeq 2500 or NovaSeq 6000 with the Kapa Biosystem’s
Library Preparation Kit, and whole-exome captured with
NimbleGen SeqCap EZ v.3.0 rapid or v.4.
Western blot
Fibroblasts were lysed in RIPA buffer (Cell Signaling
#9806) and an aliquot containing 10 µg of total protein
was boiled, separated in 4-20% CriterionTMTGXTM gels, and
transferred to 0.2 µm nitrocellulose using Trans-Blot
Turbo (all Bio-Rad). Blocking was done with 10% milk in
0.1% TBS-T. Antibodies were: IP3R1
(CT-1), IP3R2
(NT-2) (gift
from Dr. David Yule, University of Rochester, NY), IP3R3
(BD-Transduction #610312), and b-tubulin (Cell Signaling
#2146S). Anti-rabbit and anti-mouse (Jackson Immunore-
search#111-035-144 and #115-035-146) secondary antibod-
ies were used. Detection was done by WesternBrightTM
ECL-spray (Thermo Scientific) and imaging with Molecu-
lar Imager ChemiDoc XRS + with ImageLab (Bio-Rad).
Quantitative PCR and siRNA
RNA was extracted by NucleoSpin RNA extraction kit
(Macherey-Nagel #740955) and reverse transcribed by
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Maxima first strand cDNA synthesis kit (Thermo Fis-
cher). RT-qPCR was performed using DyNAmo Flash
SYBR Green qPCR Kit (Thermo Scientific) with specific
primers for ITPR1, ITPR2, ITPR3, and GAPDH
(Table S2) using Bio-Rad CFX Maestro 1.1 software (Bio-
Rad). ITPR3 siRNA knockdown experiments were con-
ducted as described19 using ITPR3 ON-TARGETplus
SMARTpool siRNA (Dharmacon #L-006209-00-0005) and
ON-TARGETplus Non-targeting siRNA (Dharmacon #D-
001810-01-05).
Fibroblast Ca2+ imaging
We performed fibroblast Ca2+ imaging by two different
methods in two different laboratories: non-ratiometric
manual Ca2+ assay using ATP stimulation (performed in
University of Helsinki), and ratiometric automated Ca2+
assay using ionomycin, thapsigargin, and bradykinin stim-
ulation (performed in KU Leuven).
Non-ratiometric manual Ca2+ assay
Cells were washed two times with Hank’s Balanced Salt
Solution (HBSS) (in mM: 130 NaCl, 2.5 KCl, 1.8 CaCl2,
1.2 MgCl2, 10 HEPES, pH 7.4) and incubated for 50 min
in dark in room temperature with 5 µg/ml Fluo-4 AM
Ca2+ indicator. After incubation, cells were washed three
times with HBSS. For imaging, coverslips were placed on
MatTek glass bottom dish (MatTek #P35G-1.5-14-C) and
imaged with Zeiss Axio Observer Z1 inverted phase con-
trast fluorescence microscope. During experiment, cells
were perfused with Multichannel systems PPS2 Peristaltic
perfusion system. Before every experiment, cells were
allowed to rest for 5 min in the stage under HBSS perfu-
sion. The excitation light was filtered through 494 nm
band pass filter and the emission light passed through a
506 nm band pass filter. Emission wavelength was cap-
tured by Photometrics Prime BSI sCMOS Camera with
ZEISS ZEN 3.1 (blue edition) imaging software. Acquisi-
tion protocol lasted a total of 12 minutes under constant
perfusion at a rate of 2 ml/min. The cells were first per-
fused with HBSS containing 1.8 mM Ca2+ for 3 min and
then with HBSS solution containing no Ca2+ (0-Ca2+
HBSS) for another 3 min. Then Ca2+ release from ER was
evoked by perfusion with 0-Ca2+ HBSS containing
80 µmol/L adenosine 5’-triphosphate (ATP) magnesium
salt (Sigma-Aldrich #A9187) for 2 min. After ATP-evoked
Ca2+ response, perfusion solution was changed back to 0-
Ca2+ HBSS for 2 min and finally back to 1.8 mmol/L Ca2+
containing HBSS solution for another 2 min to induce
store-operated Ca2+ entry (SOCE) as a positive control.
The results were analyzed using MatLab (MATLAB
R2019b) and RStudio (version 1.2.5033). Regions of
interests (cells) were masked from each experiment and
the mean pixel intensity was measured at each time point
(frame) using a modified version of the previously
described MatLab script.20,21 The baseline (F0) was
selected from the first 0- Ca2+ period, from frames with
stable intensity values. Relative intensities were calculated
by first subtracting the baseline value from each frame
and then dividing it by the baseline value [DFt/F0=(Ft-F0)/
F0]. To analyze the kinetics of the Ca
2+ response peaks,
we created an R-script, which allows automatic analysis of
the peaks. The area under the curve (AUC), peak ampli-
tude and time to peak were measured from each cell, and
the averages per coverslip were calculated. The scripts
used are available online (https://github.com/Julius
Ronkko/Ca2-analysis).
Ratiometric automated Ca2+ assay
Cytosolic Ca2+ levels of fibroblasts seeded in 96-well plates
(Greiner) were monitored using ratiometric fluorescent
Ca2+ indicator dye Fura-2 AM (Eurogentec, Belgium).
They were loaded with the Fura2-AM (1 µmol/L) at RT
for 30 min in a modified Krebs solution (in mM: 150
NaCl, 5.9 KCl, 1.2 MgCl2, 11.6 HEPES (pH 7.3), and 1.5
CaCl2). After loading, cells were rested for 30 min at RT
in the absence of Fura-2 AM to allow complete dye de-es-
terification before proceeding to analysis on a FlexStation
3 microplate reader (Molecular Devices, Sunnyvale, CA,
USA). The Ca2+ indicator was alternately excited at 340
and 380 nm and emission of fluorescence at 510 nm
recorded. EGTA was added after 30 seconds in all condi-
tions at a final concentration of 3 mmol/L. After another
60 seconds, cells were exposed to stimuli prepared in
Ca2+-free modified Krebs solution containing 3 mmol/L
EGTA and Ca2+ transients were monitored for 6 min. Ion-
omycin and the irreversible SERCA-inhibitor thapsigargin
were both added at a final concentration of 10 µmol/L
and bradykinin at a final concentration of 50 nmol/L. All
traces are shown as the ratio of both emission wavelengths
F340/F380 and were smoothened using a running average of
5. For quantification purposes, a baseline value was deter-
mined for each measurement as mean fluorescence
between 30 sec and 90 sec. Fluorescence ratio F340/F380
was then normalized to the baseline values, and AUC of
the peak, the peak amplitude (both analyzed between 90
and 450 sec) and the time to the peak were measured.
RESULTS
Autosomal dominant CMT family
The proband of the Finnish family (P1) first came to neu-
rologic investigations at age 38. His first symptoms had
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started slightly before age 30 with weakened foot dorsi-
flexion and tendency to foot drop. Around age 33 he also
started to experience increased clumsiness in his hands.
He was last evaluated at age 64. His symptoms have been
slowly progressive with increasing difficulty in walking in
rough terrain. He uses supportive insoles but has
remained ambulant without external aids. He has severe
muscle atrophy in his lower legs, hammer toes, pes cavus,
and thenar muscle atrophy (Fig. 1A). Sensation to light
pressure was decreased distally from wrists and in foot
soles. Vibration sense was decreased at ankles but present
at wrists. Foot dorsiflexion or plantarflexion did not over-
come gravity. Deep tendon reflexes were absent. His other
diseases were hypothyroidism, hypercholesterolemia, and
severe obstructive sleep apnea.
The proband had two brothers (Fig. 1B), one of whom
had no neuropathic symptoms, while the other (P3) had
pes cavus and progressive distal muscle weakness and
wasting. His diseased father (P4) had been diagnosed with
hereditary neuropathy of unknown cause but was other-
wise relatively healthy and lived to an age of 93 years. He
had remained ambulant until that age. The daughter of
the proband (P2) first came to neurologic examination at
age 35. She had had hammertoes and other deformities of
the small bones of the feet since childhood, which had
been operated on first at age 27. Despite this, she was
ambulant without aids and able to play sports. She was
able to walk on toes and heels. Marked pes cavus and
hammertoes were noted (Fig. 1C), in addition to mild
impairment of vibration sense at the right ankle.
Nerve conduction studies (NCS) of P1, P2, and P3
were consistent with demyelinating neuropathy, which
were graded at least mild. The reduction in NCV was
clearly less than is typical for CMT1A (Table 1). In addi-
tion, there was variable degrees of axonal neuropathy,
which tended to worsen with age. Biopsies from P1 had
been obtained at age 38. In sural nerve biopsy, a clear
hypertrophic neuropathy with prominent onion bulbs
was seen (Fig. 1D). Muscle biopsy from tibialis anterior
muscle showed prominent small group atrophy, fiber type
grouping, and secondary myopathic change (Fig. 1E).
Single affected individual
The proband of the Ashkenazi Jewish family (P5) was
developing normally until 4 years of age when he began
falling. An evaluation at that time was concerning for pes
cavus with hammertoes, and a motor only NCS showed a
small tibial CMAP (0.5 mV) with a demyelinating range
conduction velocity (20 m/sec). The median CMAP was
normal (4.0 mV) but the NCV was 35 m/sec. No tempo-
ral dispersion or conduction block was present in either
nerve. He was diagnosed with a demyelinating CMT and
over the intervening decade he experienced progressive
loss of leg strength and sensation in a symmetric distal to
proximal gradient. After this evaluation he was not evalu-
ated by a neurologist until 16 years of age when he estab-
lished care at Columbia University Irving Medical Center
(CUIMC).
On neurological examination at age 16, he had pes pla-
nus with complete loss of muscle below the knees, and
atrophy of proximal leg and hand intrinsic muscles. There
A
P4
P1 P3
P2
B
D E
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c.1843G>A
P2
DNA
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Figure 1. Clinical features and sequencing. Photographed at age 64,
the index patient P1 had distal muscle atrophy (A). In the family, his
father (P4) and one of his two brothers (P3) had been similarly
affected (B). Moreover his daughter (P2) had had foot deformities
since an early age and was noted to have pes cavus when examined
at age 35 (C). In sural nerve biopsy of P1, a clear hypertrophic
neuropathy with prominent onion bulbs was seen (D, plastic section
toluidine blue staining, scale bar 25 µm). Muscle biopsy from tibialis
anterior muscle of P1 showed prominent small group atrophy, fiber
type grouping and secondary myopathic change (E, frozen section
HE-staining, scale bar 125 µm). Sanger sequencing confirmed the
presence of ITPR3 c.1843G> A (p.Val615Met) in all affected
individuals, shown are P1 and P2 chromatograms (F), and it was
absent in the unaffected brother.
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was no movement at the ankles, anti-gravity strength at
the knees, and mild weakness of hip flexion and the hand
intrinsics. Temperature, pin prick, and vibration were
severely reduced at the toes and ankles, but remarkably,
joint position sense was preserved. All reflexes were
absent. Otherwise, general examination, cognitive evalua-
tion, and neurological examination were normal.
The proband was the product of a consanguineous
union (parents are second cousins). His father is known
to have flat feet and mildly reduced distal sensation in his
early 40’s but no demonstrable weakness. His mother’s
examination was normal. Of the proband’s 11 full sib-
lings, none are suspected by the family to have similar
symptoms but have not been formally tested.
Repeat EMG/NCS showed absent motor and sensory
responses in the legs (Table 1). The median and ulnar
nerves showed normal CMAP amplitudes and slowed
conduction velocities (32 m/sec), with mildly reduced
SNAP amplitudes and conduction velocities of 38 m/sec.
Genetic findings
In P1, we first excluded PMP22 duplication, MFN2 and
GJB1 mutations. After this we performed exome sequenc-
ing on P1 and P3. We filtered the exome data for (1)
shared nonsynonymous changes (excluding in frame
insertions/deletions), (2) absence in SNP database
(dbSNP), (3) prevalence ≤ 10-5 in the Finnish subpopula-
tion of gnomAD (v2.1.1), and (4) CADD score22 of 15 or
more. The analysis left nine variants (Table S3) of which
c.1843G>A (p.Val615Met) in exon 16 of ITPR3
(NM_002224.4) was of interest. We confirmed the segre-
gation of the variant with disease in the family by Sanger
sequencing (Fig. 1F). The other identified variants had no
previous studied function in Schwann cells or suggested
association with CMT.
In P5, a chromosomal analysis and SNP microarray
were within normal limits though the SNP microarray
showed long contiguous runs of homozygosity consistent
with the history of consanguinity. A CMT gene panel that
included sequencing and deletion/duplication analysis of
42 genes identified single missense variants of uncertain
significance in each of two autosomal recessive CMT
genes (IGHMBP2 and NDRG1) without other coding or
copy number variants in those genes. A clinical exome
was reported as negative. Trio sequence data were subse-
quently analyzed with an updated version of the Institute
for Genomic Medicine’s established trio sequencing
framework23 which identifies ‘‘qualifying’’ genotypes not
observed in the parents, 12,044 control individuals from
the Institute for Genomic Medicine, or two external data-
bases of 6,503 and 60,706 control individuals provided by
the National Heart, Lung, and Blood Institute (NHLBI)
Exome Sequencing Project (ESP6500SI [March 2013
release]) and the Exome Aggregation Consortium (ExAC
Browser v.0.3 [January 2015 release]), respectively. The
analysis identified a de novo missense variant in exon 55
of the ITPR3 gene (NM_002224.4, c.7570C>T,
Table 1. Clinical and neurophysiological findings.
Case P2 P1 P3 P4 P5
Ethnicity Finnish Finnish Finnish Finnish Ashkenazi Jewish
Sex F M M M M
Age at onset 20s 27 n.a. n.a. 4
Age at examination 35 63 31 Died age 93 16
Distal weakness - + + + +
Distal sensory impairment + + + + +
Foot skeletal deformity + + + n.a. +
Medianus motor conduction velocity m/s 39 33 45 n.a. 32
Medianus motor distal latency ms 4.92 7.48 4.1 n.a. 7.34
Medianus CMAP amplitude mV dist/prox 6.6/5.8 3.8/2.7 n.a. n.a. 4.0/2.9
Radialis sensory conduction velocity m/s 52 48 n.a. n.a. n.a
Radialis SNAP amplitude µV 15 7.0 n.a n.a. n.a
Median and ulnar SNAP amplitude µV n.a n.a n.a n.a 6.7/5.1
Peroneus motor conduction velocity m/s 30 n.r. 43 n.a. n.r
Peroneus motor distal latency ms 5.79 n.r. 6.4 n.a. n.r
Peroneus CMAP amplitude dist/prox mV 4.9/3.8 n.r. n.a. n.a. n.r
Tibialis CMAP amplitude dist mV 1.1 n.r. n.a. n.a. n.r
Tibialis motor distal latency ms 4.76 n.r. n.a n.a. n.r
Suralis sensory conduction velocity m/s 42 n.r. 35 n.a. n.r
Suralis SNAP amplitude µV 1.8 n.r. 4.3 n.a. n.r
CMAP: compound muscle action potential, SNAP: sensory nerve action potential, n.r. no response, n.a. not available.
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p.Arg2524Cys). The variant is absent from the gnomAD
V2.1.1 database, has a CADD score of 32.
Both ITPR3 variants are predicted to be deleterious
and damaging to protein structure and/or function based
on in silico analyses (damaging by SIFT, probably damag-
ing by PolyPhen2). The affected amino acids are highly
conserved (Fig. 2A). We assessed the affected residues
using published IP3R structures.
24-26 p.Val615 is located
in the armadillo repeat domain (ARM1), just after the
IP3-binding domain (running from aa 1 to ~ aa 600).
p.Arg2524 is located in the transmembrane domain
(TMD) and lies in the channel pore (Fig. 2B-D).
Protein and mRNA
Skin fibroblasts of P1 and P2 were available for study. We
assessed the levels of IP3R proteins and corresponding
mRNAs. IP3R3 protein level was decreased in the skin
fibroblasts of P2 but not in P1, as compared with controls
(Fig. 2E and F). However, P1 fibroblasts had significantly
elevated ITPR3 mRNA level as compared with controls
(Fig. 2G), which suggests a compensatory mRNA upregu-
lation to preserve the normal IP3R3 protein level. IP3R2
protein level was also decreased in P2, while those of
IP3R1 were unaffected. Also, ITPR1 and ITPR2 mRNA
levels were unchanged in both patient lines.
Fibroblast Ca2+ flux
Next, we performed siRNA knockdown of ITPR3 in control
fibroblasts. The knockdown was confirmed by western blot
(Fig. 3D) and led to altered Ca2+ flux dynamics in response
to GPCR agonist ATP, with delayed peak of response but
no change in amplitude or area under the curve (AUC)
(Fig. 4A). This experiment confirmed that loss of IP3R3
produces a detectable phenotype in fibroblasts.
After this, we analyzed Ca2+ homeostasis in fibroblasts
from P1 and P2 and healthy controls. The response to
GPCR agonist ATP, which results in IP3 signaling and
thus opening of IP3Rs, was analyzed by manual non-ratio-
metric assay in the absence of extracellular Ca2+. The
ATP-evoked Ca2+ release was altered in both patient
fibroblasts. P1 fibroblasts had statistically significant
decrease in AUC, while P2 fibroblasts had increased time
to peak (Fig. 4B). We performed additional Ca2+-signaling
analyses in cell populations using ratiometric automated
technique. In these experiments, cells were first exposed to
EGTA, an extracellular Ca2+ buffer. The response to the
Ca2+ ionophore ionomycin, which provides an estimate of
the total intracellular Ca2+ content, was decreased in P1
fibroblasts (Fig. 4C). The SERCA inhibitor thapsigargin,
which gives an estimate of ER Ca2+ store content, did not
cause statistically significant changes in the patient
fibroblasts (Fig. 4D). Finally, the alternative GPCR agonist
bradykinin evoked smaller cytosolic Ca2+ transients in P1
and P2 fibroblasts, the latter having significantly lower
peak amplitude (Fig. 4E). Overall, the results suggest that
the p.Val615Met mutation in ITPR3 affects Ca2+ home-
ostasis and IP3-mediated Ca
2+ release.
DISCUSSION
This study provides genetic and functional evidence for
ITPR3 as a dominant CMT disease gene. We describe two
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Figure 2. Position and conservation of IP3R3 mutations. The
p.Val615Met and the p.Arg2524Cys mutations affect conserved stretch
of amino acids (A). The p.Val615Met mutation lies adjacent to the
cytoplasmic surface of IP3R3 and in proximity to the IP3 binding site,
while the p.Arg2524Cys mutation lies in the channel pore (B-D), as
predicted based on the previously published model of the tetramer23.
The amino acids 610-620 and 2520-2530 are highlighted in red (B and
C). Key domains of IP3R3 channel and IP3-molecule at its binding site
are highlighted in the figure (D). ARM1-3 = armadillo repeat domains
1-3, BTF1-2 = b-trefoil domains 1-2, CLD = center linker domain,
JD = juxtamembrane domain, TMD = transmembrane domain.
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new mutations: p.Val615Met in adult onset and
p.Arg2524Cys in childhood onset CMT. The reduction in
median motor NCV in these patients was consistent with
demyelinating neuropathy, which was also confirmed by
nerve biopsy in one patient. However, the magnitude of
reduction was less severe than is usually observed in
CMT1A (OMIM #118220), which is the most common
form of CMT.2 Our patients’ NCV was in the 30-45 m/s
range suggesting it should be considered in those with
“intermediate CMT”.2 However, in CMT, conduction
velocities vary by nerve, disease duration and patient, thus
additional patients will be required to more conclusively
define whether this is a demyelinating or intermediate
CMT. Axonal involvement in our patients tended to
become worse with age, which suggests that the axonal
degeneration was secondary to demyelination.
Both of the identified mutations affect highly conserved
residues. Being located in the central, modulatory region
of IP3R3, shortly after the ligand-binding domain,
24 the
p.Val615Met variant might influence IP3R3 activity, for
example, through interfering with allosteric regulators.9
The p.Arg2524Cys variant, which localizes in the channel
pore, may affect the channel properties and/or the ion
flux directly, thus accounting for the earlier onset, faster
progression, and more severe phenotype in this patient.
The previously reported variant of unknown significance,
p.Thr1424Met,4 was in a patient who similarly to our
patients had moderately decreased median motor NCV of
34.7 m/s. Onset was at age 40, and two additional indi-
viduals in the same family were similarly affected.4 The
p.Thr1424Met variant localizes in the armadillo repeat
domain 2 near the subunit contact site. It may therefore
affect oligomerization of the channel. Finally the variant
p.Met1064Val, previously found in one index case of
hereditary neuropathy,5 affects a conserved residue in the
channel surface at the center linker domain. Similarly, as
p.Val615Met and p.Arg2524Cys variants, both variants
reported earlier are predicted to be deleterious and dam-
aging to protein structure and/or function (damaging by
SIFT, probably damaging by PolyPhen2). Thus the
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Figure 3. Fibroblast protein levels in Finnish family patients. Western blots of fibroblast lysates showed that the levels of IP3R1 were not changed
between patient and control fibroblasts (A, B). In P2 fibroblasts, the levels of IP3R2 and IP3R3 were significantly decreased compared with the
controls, whereas the levels in P1 fibroblasts were unchanged (A, B). qPCR showed that the mRNA level of ITPR3 was increased in P1 but not in
P2 fibroblasts (C). Finally, siRNA knockdown of ITPR3 in control fibroblasts led to clear reduction in the protein level of IP3R3 by western blot,
while the levels of IP3R1 and IP3R2 were unchanged (D) KD = ITPR3 siRNA knockdown, NT = non-targeting siRNA, wt = non-treated. Data points
marked in the figures were excluded from the data-analysis (*P < 0.05, **P < 0.01, ***P < 0.001).
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Figure 4. Ca2+ flux analysis in patient and control fibroblasts. The Ca2+ flux measurements were performed with two different methods, using
cell-permeant Fluo-4 AM and Fura-2 AM fluorescent Ca2+ indicators. In the first method (A and B), we used fluorescent microscopy to monitor
Ca2+ in single cells, and 80 lmol/L ATP as GPCR agonist to evoke Ca2+ release. In each case, representative Ca2+ response curves after addition
of ATP are shown. Grey thin lines are recordings from single cells whereas the thick line represents the averaged trace for all the cells in the given
experiment. (A) siRNA of ITPR3 led to increased average time to peak as compared with cells that were untreated (wt) or treated with non-
targeting (NT) siRNA (n = 4 individual experiments). KD = ITPR3 siRNA knockdown, NT = non-targeting siRNA, wt = non-treated. (B) In response
to ATP, P1 fibroblasts had decreased area under curve (AUC), while P2 cells had increased time to peak compared with unrelated controls (P1
n = 20, P2 n = 14 and three controls n = 17-22 individual experiments). In the second method (C–E), we measured Ca2+ in single wells of a 96-
well plate, using 10 lmol/L ionomycin, 10 lmol/L thapsigargin or 50 nmol/L bradykinin to evoke responses, and compared patient cells to one
control line performing five independent experiments in each setting. All stimuli (added after 90 sec, 2nd dotted line) were added in the presence
of EGTA (added after 30 sec, 1st dotted line). (C) Traces showed a decrease in ionomycin-induced Ca2+-transients for both patients compared to
the healthy control, with a significant decrease in peak amplitude for P2. (D) In response to SERCA inhibitor thapsigargin, patient fibroblasts did
not display statistically significant decrease in Ca2+ ER store content compared to the healthy control. (E) In response to bradykinin, we observed a
significant decrease in the peak amplitude of the response in P2 fibroblasts. All results are presented as mean  SEM of independent experiments
and statistical comparisons performed with one-way ANOVA. (*P < 0.05, **P < 0.01, ***P < 0.001).
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dominant missense variants may have different molecular
effects on IP3R3 function, which also influences disease
severity.
Our measurements of Ca2+ flux demonstrate altered
Ca2+ homeostasis in p.Val615Met patient cells. The pri-
mary fibroblasts express ITPR3 and thus are a useful tool
to study the effects of the mutation under physiological
conditions. The weakness of this model is that it does not
account for possible neuron- or Schwann cell specific
effects of the mutation. In addition, the results may be
influenced by other genetic differences between control
and patient cells in addition to the ITPR3 mutation.
Treatment with ITPR3 siRNA was used to confirm that
IP3R3 is active in fibroblasts under normal conditions
and to model the effect of loss-of-function of the channel.
We found altered GPCR agonist responses in both patient
lines. The slowed response in P2 fibroblasts was similar
but less pronounced than in siRNA-treated cells. In addi-
tion, the P1 cells showed a decreased amplitude of the
Ca2+ response to ATP. The differences in the Ca2+
responses between the two patient cell lines may be
related to reduction in the amounts of IP3R2 and IP3R3
in P2 cells, which were compensated by ITPR3 mRNA
upregulation in P1 cells. In addition, the difference in sex
or other possible genetic differences may in part account
for the differences between P1 and P2 fibroblasts. Based
on these results, the p.Val615Met variant may produce a
dominant negative effect on channel function. The effect
appears to be subtle, which is consistent with late onset
and slowly progressive nature of our patients’ phenotype.
As ionomycin and thapsigargin-induced Ca2+ release
tended to be lower in patient fibroblasts, it cannot be
excluded that IP3R3 p.Val615Met is leaky, that is, has an
increased likelihood of being open compared with the
wild type situation, thereby lowering steady state ER Ca2+
levels and thus dampening Ca2+ release in the cytosol
upon agonist exposure.
Our results suggest an important role of IP3R3 in
peripheral nerve maintenance. This is supported by its
localization in paranodal regions of rat Schwann cells,
where its proximity to another CMT gene product, gap
junction protein beta-1 (GJB1), may allow swift propaga-
tion of Ca2+ signals from cell to cell.27 Abnormal Ca2+
flux could contribute to altered axonal Ca2+ microdo-
mains that disturb mitochondrial transport, as has been
suggested for dominant mutations in the plasma mem-
brane cation channel transient receptor potential cation
channel, subfamily V, member 4 (TRPV4)28-31 which
cause CMT2C32-34. Furthermore, mutations in other com-
ponents of the IP3 signaling pathway, for example, FIG4
and SBF2, cause demyelinating CMT,35-36 which high-
lights the importance of this pathway for peripheral mye-
lin maintenance. Finally, IP3R3 has important
implications for regulation of mitochondrial function and
cell death and survival by participating in Ca2+ transfer
between ER and mitochondria,16,37 a process which is also
dependent on another important CMT gene, mitofusin 2
(MFN2).38 IP3R3 defects may decrease mitochondrial
Ca2+ and predispose to defective bioenergetic or ER
membrane function, which have been found in other
forms of CMT.39,40
In conclusion, our results provide further evidence that
ITPR3 is a disease gene for CMT. Additional studies, ide-
ally in neuronal or animal models, will be needed to elu-
cidate the effects of the disease variants on IP3R3
function and evaluate the potential of targeting Ca2+ flux
as a therapeutic target in CMT.
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